Michael is a senior drug development professional with over 25 years’ professional experience in the life sciences industry, having served inleadership positions across a wide range of disciplines, in both small to mid-sized biotech and large global corporations.
As Co-Founder, Board Member and CEO of Cellestia from 2015 – 2022 he has led the formation of Cellestia Biotech AG starting from an EPFL spin-off project to an integrated R&D company. Under his leadership, Cellestia has successfully completed a global First-in-Man clinical trial demonstrating excellent safety and biologic proof of concept, established a diagnostic patient selection program and led the set-up of a multi-indication Ph2 program in oncology and Ph1 GvHD. In addition, a rich and diversified follow-on pipeline has been built, with next projects ready for IND enabling studies including arange of un-disclosed discovery programs based on the company´s discovery platform targeting novel gene transcription factors.
“My passion is translating groundbreaking science, novel modes of action and new therapeutic approaches into innovative medicines for patients. During the past years it has been extremely rewarding and motivating to deliver a breakthrough in biomedical research: We have found a way to target oncogenic and pro-inflammatory signaling of NOTCH with outstanding safety and potency”
Prior to co-founding Cellestia Michael held various senior leadership positions of increasing responsibility with Novartis Pharma AG, Polyphor Ltd., Arpida Ltd., Syngenta AG and Zeneca PLC. Under his leadership, several new oncology drugs were brought into clinical development, some of these later reaching regulatory approval. Michael holds a Ph.D. in Biotechnology from Technical University of Hamburg-Harburg and an M.Sc. in Chemistry from University of Hamburg, Germany.